S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview

S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview

From Oncology On The Go by CancerNetwork

May 28, 2026 · 29 min · Season 1 · Episode 216

About this episode

Nicholas Hornstein discusses advancements in GI oncology and the evolving landscape of colorectal cancer treatment ahead of the 2026 ASCO Annual Meeting.

In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal Cancer Hornstein highlighted the increasing integration of targeted therapies into the first-line setting for patients with colorectal cancer (CRC). For those with BRAF V600E-mutated metastatic disease, data from the phase 3 BREAKWATER trial (NCT04607421) support moving targeted therapy into the first line.1 He noted that initiating these therapies early is critical, as a significant percentage of patients may experience rapid clinical decline and lose the opportunity for second-line treatment if targeted options are delayed. In the HER2-positive space, clinicians currently utilize tucatinib (Tukysa)-based regimens or fam-trastuzumab deruxtecan-nxki (Enhertu). Hornstein also anticipated the arrival of bispecific antibodies, such as zanidatamab-hrii (Ziihera), which are expected to gain…

More episodes of Oncology On The Go

Explore listener stats, chart rankings, contacts and more on the Oncology On The Go podcast page.